Actylis Announces Appointment of Scott Thomson as Chief Executive Officer

Company Continues Expansion of Integrated Global Specialty Ingredients Manufacturing and Sourcing Strategy

Actylis, a leading global manufacturer and sourcing expert of critical materials and performance ingredients for the life sciences and specialty chemicals markets, today announced the appointment of Scott Thomson as Chief Executive Officer. Scott has a three-decade track record in the pharmaceutical and chemical industries, most recently as CEO of SPI Pharma, a leading global provider of pharmaceutical ingredients, systems and services, where he helped lead the sustainable improvement of its strategic development and execution. Prior to SPI Pharma, Scott was a senior executive at BASF and was responsible for several global life science and specialty ingredients businesses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240617272197/en/

“Scott has an impressive tenure of driving long-term growth, and we look forward to welcoming Scott as we bring our client-centric, flexible customer service model and extensive product offerings to an increasing number of geographies, customers and applications,” said Rakesh Sachdev, Chairman of Actylis. “We also want to thank Gilles Cottier for his leadership as CEO of Actylis over the last five years and wish him well in his retirement.”

Joe Walker, Managing Director at New Mountain Capital, said, “Since New Mountain’s investment in 2019, Actylis has transformed into a leading manufacturer and distributor of key ingredients in pharma, biopharma, nutritional, agri-science, cosmetics and specialty chemicals markets, completing seven acquisitions and substantially expanding the company’s global reach. We are excited for Scott to leverage and accelerate Actylis’ strong growth trajectory with increasing emphasis on high growth end markets and products.”

Andre Moura, Managing Director at New Mountain Capital, added, “Actylis has tremendous runway for sustainable growth due to its strong value proposition and market positioning. We are thrilled to invest further and support Scott and the management team to realize the company’s long-term strategic vision.”

Actylis offers standard and custom ingredients through a rapidly growing portfolio of GMP and non-GMP facilities worldwide, as well as through the company’s strong sourcing partner network. Actylis’ hybrid manufacturing and global sourcing model for ingredients and raw materials delivers the most flexible and reliable solutions for its customers’ unique manufacturing requirements, supported by industry-leading standards of quality documentation and regulatory compliance.

Scott Thomson, CEO of Actylis, commented, “I feel privileged to lead the Actylis team at this exciting juncture, and I look forward to partnering with our customers, Actylis’ management and employees, and New Mountain to grow and further develop Actylis’ offerings. There is significant opportunity to accelerate the company’s growth and I look forward to building upon the company’s achievements to date both organically and inorganically.”

About Actylis

Actylis is a leading global manufacturer and sourcing expert of critical materials and performance ingredients for the life sciences and specialty chemicals markets. Actylis has a presence in 10 countries spanning three continents and offers more than 4,000 products supported by over 800 employees. Actylis has more than 75 years of manufacturing and sourcing experience across both GMP and non-GMP facilities and offers customers the flexibility to choose from a wide range of individualized solutions, all backed by the same world-class quality, supply chain reliability and regulatory expertise. Its capabilities encompass the entire R&D, product development and manufacturing spectrum, including technical sales support, R&D, manufacturing and production, quality, supply chain, global sourcing, and regulatory compliance. Actylis serves pharmaceutical, biopharmaceutical, nutritional, cosmetics, agri-science and specialty chemical end markets. The company is headquartered in Port Washington, New York. https://actylis.com/

About New Mountain Capital

New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, credit and net lease investment strategies with approximately $50 billion in assets under management. New Mountain Capital seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit https://www.newmountaincapital.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240617272197/en/